Resilience is building the world’s most advanced biopharmaceutical manufacturing ecosystem.

In light of the pandemic, manufacturing supply chains are needed that can withstand disruptive shocks and safeguard health security. Resilience is changing the way medicine is made – leveraging innovation to better serve scientific discovery, withstand disruptive events, and reach those in need.
-
Industry
-
Milestones
- Lux investment: 2020
-
Founders
- Bob Nelsen
- Rahul Singhvi
- Sandy Mahatme
- Patrick Y. Yang
LUX Partners